TABLE 3.

Summary of time to first ADA detection during treatment with emicizumab

		Time to first treatment‐induced or treatment‐boosted ADA
PwHA (N = 668)	n	≤1 month	>1 to ≤2 months	>2 to ≤3 months	>3 to ≤6 months	>6 months
ADA‐positive PwHA	34	3 (8.8%)	4 (11.8%)	9 (26.5%)	14 (41.2%)	4 (11.8%)
nADA‐positive PwHA a	18	2 (11.1%)	2 (11.1%)	7 (38.9%)	6 (33.3%)	1 (5.6%)

Abbreviations: ADA, anti‐drug antibody; nADA, neutralising anti‐drug antibody; PwHA, persons with haemophilia A.

^a Including ADA‐positive PwHA with decreased exposure.